fda warning letters glp-1 september 2025 The U.S. Food and Drug Administration (FDA) has issued a to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its medications Novo Nordisk Warned Over Drug

Related Reading: FAQs About GLP-1 Medications What About GLP-2

Administration of GLP-1 Most GLP-1 therapies are injected subcutaneously, under the skin

Blue Cross Blue Shield (BCBS) coverage for GLP-1 medications like Wegovy and Ozempic remains inconsistent across state plans and employer groups

Programs were filtered against four criteria: clinician oversight (real review, not rubber-stamping), pharmacy quality (state-licensed, ideally 503(a) or 503B disclosure), pricing transparency (no surprise dose escalation), and refund-policy clarity (terms readable before paying)

Sci Signal 8 , ra27, 10.1126/scisignal.aaa0899 (2015)